Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis

Published:2019-04 Issue:5 Volume:17 Page:838-846.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Peyrin-Biroulet Laurent,Danese Silvio,Argollo Marjorie,Pouillon Lieven,Peppas Spyros,Gonzalez-Lorenzo Marien,Lytras Theodore^ORCID,Bonovas Stefanos

Funder

Takeda

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference51 articles.

1. Novel therapeutic targets for inflammatory bowel disease;Argollo;J Autoimmun,2017

2. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease;Pouillon;Expert Opin Biol Ther,2016

3. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review;Gisbert;Am J Gastroenterol,2009

4. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review;Billioud;Am J Gastroenterol,2011

5. An overview of the mechanism of action of the monoclonal antibody vedolizumab;Wyant;J Crohns Colitis,2016

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction;Journal of Clinical Medicine;2024-07-09

3. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

4. Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn’s Disease;Journal of Crohn's and Colitis;2024-06-05

5. Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study;Clinical Gastroenterology and Hepatology;2024-05